Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV


Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV

Topic: Gastroenterology
Relevant Terms: Hepatitis, HCV, SVR, Interferon-free, Cirrhosis, HIV/HCV Coinfection, Liver Transplant, Genotype 1
Primary Audience: The intended audience for the activities is gastroenterologists, hepatologists, nurse practitioner and physician assistant HCV specialists, and other health care professionals involved in the treatment of patients with HCV.
Launch Date: 18-May-15
Credits: AMA PRA Category 1 Credits
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discuss the importance of HCV treatment and achievement of sustained viral response for improvement of hepatic and extrahepatic manifestations in mild as well as severe disease.
  2. Apply the clinical evidence to optimize treatment duration, monitoring strategies, and drug-drug interactions for newly approved and emerging interferon-free regimens.
  3. Appraise the clinical evidence to determine how to optimize the use of newly approved and emerging interferon-free regimens in special populations of patients including those with decompensated cirrhosis, HIV/HCV coinfection, transplant/post-transplant of liver, renal impairment, and HCV genotype 3.


    Ira Jacobson, MD
    Chairman, Department of Medicine
    Mount Sinai Beth Israel Medical Center
    Vice Chair of Medicine
    Mount Sinai Health Care System
    Senior Faculty, Icahn School of Medicine at Mount Sinai
    New York, NY
    Andrew Muir, MD, MHS                    
    Chief, Division of Gastroenterology
    Director GI/Hepatology Research Group
    Associate Professor of Medicine      
    Department of Medicine                         
    Duke University                                                
    Durham, NC
    Nancy Reau, MD
    Associate Professor of Medicine
    University of Chicago
    Chicago, IL
    Mark Sulkowski, MD
    Professor of Medicine
    Medical Director of the Viral Hepatitis Center
    Johns Hopkins School of Medicine
    Baltimore, MD
    This continuing medical education activity is provided by .

    This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

    This program is not affiliated with Digestive Disease Week®.

    Time Title Speaker
    6:30 pm - 6:35 pm Introduction and Pretest Ira Jacobson, MD
    6:35 pm - 6:55 pm The Value Proposition of Achieving SVR: Multifaceted Benefits and Managing Resource Challenges Nancy Reau, MD
    6:55 pm - 7:20 pm Initial Treatment for a Patient with HCV Genotype 1: Considerations for Interferon-Free Treatment Regimens Ira Jacobson, MD
    7:20 pm - 7:45 pm Retreatment When Prior Therapy Has Failed Andrew Muir, MD, MHS
    7:45 pm - 8:05 pm Key Points for the Use of New HCV Therapies in Distinct Populations Mark Sulkowski, MD
    8:05 pm - 8:15 pm Posttest Ira Jacobson, MD
    8:15 pm - 8:30 pm Question and Answer  
    Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
    Credit Designation
    Vindico Medical Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
    American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours credit for completing this program.
    This educational activity is designed for AMA PRA Category 1 Credit(s)™ for US physicians only. All non-US physicians should contact their respective Boards for accreditation/credit status.

    Unlabeled and Investigational Usage
    The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
    ADA Compliance
    In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities.
    Disclaimer – Vindico Medical Education
    The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
    Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Vindico Office of Medical Affairs and Compliance.

    Faculty Disclosure
    In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.
    Scheduled speakers of "Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV" on Monday, May 18, 2015 have provided the following disclosure information, which is accurate at the time of launch.
    Faculty Member Relationship identified with
    Ira Jacobson, MD Consulting Fee: AbbVie, Achillion, Alnylam, Bristol-Myers Squibb, Enanta, Gilead, Janssen, Merck
    Speakers Bureau: AbbVie, Bristol-Myers Squibb, Gilead, Janssen
    Contracted Research: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, Tobira
    Andrew Muir, MD, MHS Consulting Fee: AbbVie, Achillion, Bristol-Myers Squibb, Gilead, Janssen, Merck, Theravance
    Contracted Research: AbbVie, Achillion, Bristol-Myers Squibb, Gilead, Janssen, Merck, Roche, Theravance
    Nancy Reau, MD Consulting Fee: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Salix
    Contracted Research: AbbVie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Merck
    Mark Sulkowski, MD Consulting Fee: AbbVie, Achillion, Gilead, Janssen, Merck
    Contracted Research (paid directly to institution): AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck
    Peer Reviewer Relationship identified with
    Joseph K. Lim, MD Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Merck
    Contracted Research: Abbott, Bristol-Myers Squibb, Gilead, Hologic, Janssen
    Ronald A. Codario, MD, FACP, FNLA, CCMEP No relevant financial relationship to disclose.
    Vindico Medical Education Staff: No relevant financial relationships to disclose. 
    Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.